{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:01:36Z","timestamp":1778227296326,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Approximately 26% of adult women in the United States suffer from female sexual arousal disorder (FSAD), yet little has been done to compare the experience of FSAD in pre- and postmenopausal women, which is critical to enhance the current understanding of FSAD and inform the development and assessment of treatment options for these patient populations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To explore the experience of condition-associated symptoms and the relative importance of FSAD symptoms, including their severity, bother, and impact, on participants\u2019 health-related quality of life (HRQoL) in pre- and postmenopausal women with FSAD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In-depth, qualitative, semistructured concept elicitation interviews were conducted with premenopausal (n\u2009=\u200923) and postmenopausal (n\u2009=\u200913) women who were clinically diagnosed with FSAD by a trained sexual medicine clinician. All interviews were audio recorded and transcribed verbatim by a professional transcription company. Thematic analysis was performed with the assistance of NVivo qualitative analysis software.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Outcomes included qualitative interview data about FSAD symptoms and HRQoL, as well as a comparison between pre- and postmenopausal populations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most frequently reported symptom in both cohorts was \u201cinability or difficulty with orgasm\u201d (premenopausal, n = 21; postmenopausal, n = 13). The symptom that premenopausal women most desired to have treated was lubrication, and for postmenopausal women, it was a lack of lubrication or wetness and loss of feeling\/sensation. In total, 21 of 23 premenopausal women and all 13 postmenopausal women reported a lack of feeling or sensation in the genitals. The most frequently reported HRQoL impact in both groups was decreased confidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Results from this study suggest that the manifestation and experience of FSAD are similar in pre- and postmenopausal women and that the unmet need for an FSAD treatment in the postmenopausal population is just as great as that of the premenopausal population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>This study involved in-depth qualitative interviews with a relatively small group of women (N\u2009=\u200936) recruited from only 5 study sites across the United States.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The analysis of qualitative data from the concept elicitation interviews revealed a substantial physical and emotional burden of FSAD, underscoring the need for Food and Drug Administration\u2013approved treatment options for pre- and postmenopausal women with FSAD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdac043","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T08:51:39Z","timestamp":1674463899000},"page":"277-286","source":"Crossref","is-referenced-by-count":7,"title":["Symptoms and associated impact in pre- and postmenopausal women with sexual arousal disorder: a concept elicitation study"],"prefix":"10.1093","volume":"20","author":[{"given":"Tara","family":"Symonds","sequence":"first","affiliation":[{"name":"Clinical Outcomes Solutions, Folkestone , Kent, CT19 4RH ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl A","family":"Kingsberg","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center Division of Behavioral Medicine, Department of OBGYN, , Cleveland, OH 44106 ,","place":["United States"]},{"name":"Case Western Reserve University Departments of Reproductive Biology, Psychiatry, and Urology, School of Medicine, , Cleveland, OH 44106 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A","family":"Simon","sequence":"additional","affiliation":[{"name":"George Washington University Department of OBGYN, , Washington, DC 20052 ,","place":["United States"]},{"name":"IntimMedicine Specialists , Washington, DC 20036 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Kroll","sequence":"additional","affiliation":[{"name":"Seattle Clinical Research Center , Seattle, WA 98105 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley E","family":"Althof","sequence":"additional","affiliation":[{"name":"Case Western Reserve University Department of Psychiatry, School of Medicine, , Cleveland, OH 44106 ,","place":["United States"]},{"name":"Center for Marital and Sexual Health of South Florida , West Palm Beach, FL 33401 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon J","family":"Parish","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College , New York, NY 10021 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A","family":"Cornell","sequence":"additional","affiliation":[{"name":"Strategic Science and Technologies , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella F","family":"Johnson","sequence":"additional","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA 92122 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA 92122 ,","place":["United States"]},{"name":"Center for Vulvovaginal Disorders , Washington, DC 20037 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"2025090804314723900_ref1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/187152509789541882","article-title":"Female sexual dysfunction: therapeutic options and experimental challenges","volume":"7","author":"Allahdadi","year":"2009","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"2025090804314723900_ref2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2217\/17455057.2.3.331","article-title":"Topical alprostadil for the treatment of female sexual arousal disorder","volume":"2","author":"Costabile","year":"2006","journal-title":"Womens Health (Lond)"},{"issue":"3","key":"2025090804314723900_ref3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.sxmr.2016.03.002","article-title":"Prevalence of female sexual dysfunction among premenopausal women: a systematic review and meta-analysis of observational studies","volume":"4","author":"McCool","year":"2016","journal-title":"Sex Med Rev"},{"key":"2025090804314723900_ref4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.maturitas.2016.09.013","article-title":"Female sexual dysfunction (FSD): prevalence and impact on quality of life (QoL)","volume":"94","author":"Nappi","year":"2016","journal-title":"Maturitas"},{"key":"2025090804314723900_ref5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/AOG.0b013e3181898cdb","article-title":"Sexual problems and distress in United States women: prevalence and correlates","volume":"112","author":"Shifren","year":"2008","journal-title":"Obstet Gynecol"},{"key":"2025090804314723900_ref6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsxm.2020.07.007","article-title":"Prevalence of low sexual desire with associated distress across the adult life span: an Australian cross-sectional study","volume":"17","author":"Zheng","year":"2020","journal-title":"J Sex Med"},{"key":"2025090804314723900_ref7","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"American Psychiatric Association","year":"1994"},{"key":"2025090804314723900_ref8","volume-title":"International Classification of Diseases and Related Health Problems.","author":"World Health Organization","year":"2019"},{"issue":"3","key":"2025090804314723900_ref9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jsxm.2019.01.010","article-title":"Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions\u2014part III","volume":"16","author":"Parish","year":"2019","journal-title":"J Sex Med"},{"key":"2025090804314723900_ref10","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th"},{"key":"2025090804314723900_ref11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s10508-013-0247-1","article-title":"Female sexual interest\/arousal disorder: a diagnosis out of thin air","volume":"43","author":"Balon","year":"2014","journal-title":"Arch Sex Behav"},{"key":"2025090804314723900_ref12","first-page":"35","article-title":"Sexual function and quality of life: endpoints and outcomes","volume":"4","author":"Derogatis","year":"2001","journal-title":"J Gend Specif Med"},{"key":"2025090804314723900_ref13","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1038\/sj.ijir.3900596","article-title":"Female sexual arousal disorder: new insights","volume":"12","author":"Goldstein","year":"2000","journal-title":"Int J Impot Res"},{"key":"2025090804314723900_ref14","first-page":"2877","article-title":"Female sexual dysfunction: prevalence and risk factors","volume":"7","author":"Jaafarpour","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"2025090804314723900_ref15","volume-title":"The Voice of the Patient: A Series of Reports from the US Food and Drug Administration\u2019s (FDA\u2019s) Patient-Focused Drug Development Initiative\u2014Female Sexual Dysfunction","author":"Center for Drug Evaluation and Research","year":"2015"},{"key":"2025090804314723900_ref16","first-page":"281","article-title":"Sexual dysfunction in women: a practical approach","volume":"92","author":"Faubion","year":"2015","journal-title":"Am Fam Physician"},{"key":"2025090804314723900_ref17","doi-asserted-by":"crossref","DOI":"10.1001\/jama.281.6.537","article-title":"Sexual dysfunction in the United States: prevalence and predictors","volume":"281","author":"Laumann","year":"1999","journal-title":"JAMA"},{"key":"2025090804314723900_ref18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.sxmr.2020.12.001","article-title":"FDA decisions on measures of hypoactive sexual desire disorder in women: a history, with grounds to consider clinical judgment","volume":"9","author":"Pyke","year":"2021","journal-title":"Sex Med Rev"},{"key":"2025090804314723900_ref19","volume-title":"Low Sexual Interest, Desire, and\/or Arousal in Women: Developing Drugs for Treatment\u2014Draft Guidance for Industry","author":"Center for Drug Evaluation and Research","year":"2016"},{"key":"2025090804314723900_ref20","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/j.1743-6109.2011.02312.x","article-title":"Content validity of the Female Sexual Function Index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder","volume":"8","author":"Revicki","year":"2011","journal-title":"J Sex Med"},{"key":"2025090804314723900_ref21","volume-title":"Qualitative Methods for Health Research","author":"Green","year":"2018"},{"key":"2025090804314723900_ref22","doi-asserted-by":"crossref","DOI":"10.4135\/9781446217870","volume-title":"Qualitative Health Psychology: Theories and Methods","author":"Murray","year":"1999"},{"key":"2025090804314723900_ref23","volume-title":"Introducing Qualitative Research in Psychology","author":"Willig","year":"2013"},{"key":"2025090804314723900_ref24","volume-title":"NVivo","author":"QSR International"},{"key":"2025090804314723900_ref25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/20\/3\/277\/49344698\/qdac043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/20\/3\/277\/49344698\/qdac043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T08:32:00Z","timestamp":1757320320000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/20\/3\/277\/6995419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,23]]},"published-print":{"date-parts":[[2023,2,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdac043","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2023,1,23]]}}}